Works matching IS 00099236 AND DT 2019 AND VI 105 AND IP 3
Results: 34
ASCPT News.
- Published in:
- 2019
- Publication type:
- Proceeding
In This Issue.
- Published in:
- 2019
- Publication type:
- Table of Contents
Highlights.
- Published in:
- 2019
- Publication type:
- Abstract
From Molecule to Patient and Ways to Get the Dose Precisely Right.
- Published in:
- 2019
- By:
- Publication type:
- Editorial
Pediatric Anthracycline‐Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem‐Cell Modeling.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 614, doi. 10.1002/cpt.1311
- By:
- Publication type:
- Article
When Learn/Confirm Leads to Expand/Understand: The Expanding Role of Quantitative Systems Pharmacology in the Betterment of Therapeutics Development.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 558, doi. 10.1002/cpt.1287
- By:
- Publication type:
- Article
The Fourth Hurdle.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 561, doi. 10.1002/cpt.1264
- By:
- Publication type:
- Article
Effects of Nicotine Metabolic Rate on Withdrawal Symptoms and Response to Cigarette Smoking After Abstinence.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 641, doi. 10.1002/cpt.1238
- By:
- Publication type:
- Article
Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 684, doi. 10.1002/cpt.1251
- By:
- Publication type:
- Article
Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Lessons From PBPK Modeling and Clinical Study.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 761, doi. 10.1002/cpt.1249
- By:
- Publication type:
- Article
A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance).
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 738, doi. 10.1002/cpt.1241
- By:
- Publication type:
- Article
Hospital‐Acquired Hyperkalemia Events in Older Patients Are Mostly Due to Avoidable, Multifactorial, Adverse Drug Reactions.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 754, doi. 10.1002/cpt.1239
- By:
- Publication type:
- Article
A Rapid Method to Estimate Hepatocyte Loss Due to Drug‐Induced Liver Injury.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 746, doi. 10.1002/cpt.1254
- By:
- Publication type:
- Article
Co‐Prescription of Strong CYP1A2 Inhibitors and the Risk of Tizanidine‐Associated Hypotension: A Retrospective Cohort Study.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 703, doi. 10.1002/cpt.1233
- By:
- Publication type:
- Article
Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 730, doi. 10.1002/cpt.1232
- By:
- Publication type:
- Article
Patient‐Focused Drug Development Methods for Benefit–Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 672, doi. 10.1002/cpt.1231
- By:
- Publication type:
- Article
Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV‐1 Transcription in a Phase IIb Trial.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 692, doi. 10.1002/cpt.1220
- By:
- Publication type:
- Article
Clinical Factors and Rate of Cough During Angiotensin‐Converting Enzyme Inhibitor Treatment.
- Published in:
- 2019
- By:
- Publication type:
- Letter to the Editor
Response to "Clinical Factors and Rate of Cough During Angiotensin‐Converting Enzyme Inhibitor Treatment".
- Published in:
- 2019
- By:
- Publication type:
- Letter to the Editor
Response to "Discontinuation of Angiotensin Converting Enzyme Inhibitors Due to Dry Cough: Incidence and Clinical Determinants".
- Published in:
- 2019
- By:
- Publication type:
- Letter to the Editor
Use of a Systems Pharmacology Model Based Approach Toward Dose Optimization of Parathyroid Hormone Therapy in Hypoparathyroidism.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 710, doi. 10.1002/cpt.1200
- By:
- Publication type:
- Article
Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 568, doi. 10.1002/cpt.1163
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 525, doi. 10.1002/cpt.1152
- Publication type:
- Article
Discontinuation of Angiotensin Converting Enzyme Inhibitors due to Dry Cough: Incidence and Clinical Determinants.
- Published in:
- 2019
- By:
- Publication type:
- Letter to the Editor
Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 719, doi. 10.1002/cpt.1205
- By:
- Publication type:
- Article
Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 598, doi. 10.1002/cpt.1124
- By:
- Publication type:
- Article
Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 582, doi. 10.1002/cpt.1123
- By:
- Publication type:
- Article
Regulatory Frameworks in Times of Uncertainty.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 553, doi. 10.1002/cpt.1122
- By:
- Publication type:
- Article
Surrogate Endpoints in Pediatric Studies Submitted to the US FDA.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 555, doi. 10.1002/cpt.1117
- By:
- Publication type:
- Article
Pharmacogenetics of Clopidogrel Therapy and Neurointerventional Procedures: We Need Precision Data for Precision Medicine.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 547, doi. 10.1002/cpt.1105
- By:
- Publication type:
- Article
Influence of CYP2C19 Phenotype on the Effect of Clopidogrel in Patients Undergoing a Percutaneous Neurointervention Procedure.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 661, doi. 10.1002/cpt.1067
- By:
- Publication type:
- Article
Genomic Variation and Pharmacokinetics in Old Age: A Quantitative Review of Age‐ vs. Genotype‐Related Differences.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 625, doi. 10.1002/cpt.1057
- By:
- Publication type:
- Article
Cough and ACE Inhibitors: The Truth Beyond Placebo.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 550, doi. 10.1002/cpt.1040
- By:
- Publication type:
- Article
Rate of Cough During Treatment With Angiotensin‐Converting Enzyme Inhibitors: A Meta‐Analysis of Randomized Placebo‐Controlled Trials.
- Published in:
- Clinical Pharmacology & Therapeutics, 2019, v. 105, n. 3, p. 652, doi. 10.1002/cpt.1018
- By:
- Publication type:
- Article